CD79B and acute lymphoblastic leukemia: Here, we show that surface (s)CD79b is expressed in different subgroups of pediatric BCP-ALL patients and that targeting CD79b with a monoclonal antibody reduced CNS involvement of sCD79b positive (sCD79b+) PDX samples in vivo.